Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

26.82 -0.14 (-0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 940,915
Open 26.95
Bid (Size) 26.41 (2)
Ask (Size) 27.50 (1)
Prev. Close 26.96
Today's Range 26.20 - 27.43
52wk Range 11.70 - 34.13
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
From Novocure
Via Business Wire

Performance

YTD
-10.55%
-10.55%
1 Month
-12.02%
-12.02%
3 Month
+66.10%
+66.10%
6 Month
+42.91%
+42.91%
1 Year
+84.30%
+84.30%

More News

Read More
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
Via Benzinga
Why NovoCure Stock Was Winning Big This Week
Via The Motley Fool
Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds
Via Investor's Business Daily
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Via Benzinga
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
Navigating 5 Analyst Ratings For NovoCure
Via Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
Via Benzinga
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Zai Lab
Via Business Wire
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Novocure
Via Business Wire
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
From Novocure
Via Business Wire
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
From Novocure
Via Business Wire
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Novocure Appoints Christoph Brackmann as Chief Financial Officer
From Novocure
Via Business Wire
Novocure Reports Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.